EverSource Wealth Advisors LLC Boosts Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

EverSource Wealth Advisors LLC raised its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 143.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,118 shares of the medical equipment provider’s stock after purchasing an additional 1,247 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Zimmer Biomet were worth $224,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its stake in shares of Zimmer Biomet by 2.6% in the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock valued at $524,942,000 after buying an additional 125,852 shares in the last quarter. Van ECK Associates Corp lifted its holdings in Zimmer Biomet by 5.9% in the fourth quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider’s stock valued at $417,814,000 after acquiring an additional 218,688 shares during the period. Hotchkis & Wiley Capital Management LLC boosted its position in shares of Zimmer Biomet by 49.1% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock worth $189,161,000 after purchasing an additional 577,320 shares in the last quarter. Equity Investment Corp grew its stake in shares of Zimmer Biomet by 57.2% during the 4th quarter. Equity Investment Corp now owns 1,021,062 shares of the medical equipment provider’s stock worth $107,855,000 after purchasing an additional 371,653 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its holdings in shares of Zimmer Biomet by 0.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,006,217 shares of the medical equipment provider’s stock valued at $108,621,000 after purchasing an additional 4,388 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

ZBH stock opened at $110.10 on Monday. The stock has a market capitalization of $21.92 billion, a price-to-earnings ratio of 24.74, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 52-week low of $97.69 and a 52-week high of $133.90. The stock’s fifty day simple moving average is $105.83 and its 200-day simple moving average is $106.92.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period last year, the business posted $2.20 EPS. Equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is 21.57%.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.95% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

ZBH has been the topic of several recent analyst reports. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. Royal Bank of Canada reduced their price objective on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, February 7th. JMP Securities reiterated a “market outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Stifel Nicolaus raised their price target on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.